MX359711B - Composiciones de éster de ácido graso omega-3. - Google Patents

Composiciones de éster de ácido graso omega-3.

Info

Publication number
MX359711B
MX359711B MX2014011596A MX2014011596A MX359711B MX 359711 B MX359711 B MX 359711B MX 2014011596 A MX2014011596 A MX 2014011596A MX 2014011596 A MX2014011596 A MX 2014011596A MX 359711 B MX359711 B MX 359711B
Authority
MX
Mexico
Prior art keywords
omega
fatty acid
compositions
acid ester
ester compositions
Prior art date
Application number
MX2014011596A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011596A (es
Inventor
Sancilio Frederick
Persicaner Peter
Cacace Janice
Dahim Mohand
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359711(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MX2014011596A publication Critical patent/MX2014011596A/es
Publication of MX359711B publication Critical patent/MX359711B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
MX2014011596A 2012-03-30 2013-03-11 Composiciones de éster de ácido graso omega-3. MX359711B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618161P 2012-03-30 2012-03-30
PCT/US2013/030211 WO2013148136A1 (en) 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions

Publications (2)

Publication Number Publication Date
MX2014011596A MX2014011596A (es) 2015-07-06
MX359711B true MX359711B (es) 2018-10-08

Family

ID=47998519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011596A MX359711B (es) 2012-03-30 2013-03-11 Composiciones de éster de ácido graso omega-3.

Country Status (19)

Country Link
US (9) US9302016B2 (enExample)
EP (2) EP3072510B1 (enExample)
JP (1) JP6359517B2 (enExample)
KR (1) KR102193214B1 (enExample)
CN (2) CN104321053A (enExample)
AU (1) AU2013240427B2 (enExample)
CA (1) CA2867168A1 (enExample)
CO (1) CO7121328A2 (enExample)
DK (1) DK3072510T3 (enExample)
ES (1) ES2741560T3 (enExample)
HK (1) HK1204978A1 (enExample)
HR (1) HRP20191392T1 (enExample)
IL (3) IL249821B (enExample)
IN (1) IN2014DN08449A (enExample)
MX (1) MX359711B (enExample)
MY (1) MY189576A (enExample)
PT (1) PT3072510T (enExample)
RU (1) RU2633862C2 (enExample)
WO (1) WO2013148136A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
DK2424356T3 (en) 2009-04-29 2017-12-04 Amarin Pharmaceuticals Ie Ltd STABLE PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR USING SAME
CA2759176C (en) 2009-04-29 2016-03-15 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG177254A1 (en) 2009-06-15 2012-02-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
SI2800563T1 (sl) 2012-01-06 2018-11-30 Omthera Pharmaceuticals Inc. Z DPA obogateni sestavki omega-3 polinenasičenih maščobnih kislin v obliki proste kisline
HK1204978A1 (zh) 2012-03-30 2015-12-11 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物
ES3040261T3 (en) 2012-06-29 2025-10-29 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016046680A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of liver metabolic diseases
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
HK1243324A1 (zh) 2015-01-21 2018-07-13 持田制药株式会社 ω3脂肪酸的自乳化组合物
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
JP2018537513A (ja) * 2015-12-18 2018-12-20 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びその使用方法
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
BR112018068855A2 (pt) * 2016-03-16 2019-01-22 Omegatri As pós e comprimidos que compreendem os derivados de ácido graxos de omega-3 e os métodos de sua produção
AU2017301077B2 (en) * 2016-08-12 2022-07-07 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法
JP7391977B2 (ja) * 2019-02-01 2023-12-05 マース インコーポレーテッド ネコ科動物用飼料組成物
KR20220122616A (ko) 2019-11-12 2022-09-02 애머린 파마슈티칼스 아일랜드 리미티드 심방 세동 및/또는 심방 조동을 갖는 대상체에서 심혈관 사건의 위험을 감소시키는 방법
WO2021183749A1 (en) 2020-03-12 2021-09-16 Sancilio Fred D A composition comprising docosahexaenoic acid and egg yolk suitable for sickle cell disease treatment
WO2022094203A1 (en) * 2020-10-30 2022-05-05 The Trustees Of The University Of Pennsylvania Lipid prophylactic brain injury treatment
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4992476A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Skin cleansing and moisturizing composition and method of using and preparing same
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE64761B1 (en) 1989-02-16 1995-09-06 British Tech Group Dispensing device
US5320798A (en) 1993-02-17 1994-06-14 Exxon Chemical Patents, Inc. Method for processing polyolefins at high shear rates
US5585192A (en) 1995-10-02 1996-12-17 Eastman Chemical Company Waterborne polyolefin adhesion promoter
JP4761093B2 (ja) 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP2368445A1 (en) 2002-06-18 2011-09-28 Martek Biosciences Corporation Stable Emulsions of Oils in Aqueous Solutions and Methods for Producing Same
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
CN1856294A (zh) 2003-08-25 2006-11-01 弗米克斯有限公司 渗透性药物泡沫
EP1684739A4 (en) 2003-11-12 2006-12-06 Childrens Medical Center TREATMENT AND PREVENTION OF LIVER DISEASES RELATED TO PARENTERAL DIET (PN)
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
CA2557927A1 (en) 2004-03-04 2005-09-15 Htl High-Tech Lipids Ltd. Structured triglycerides and emulsions comprising same
JP2008505177A (ja) 2004-07-01 2008-02-21 ザ・シェペンズ・アイ・リサーチ・インスティテュート・インコーポレーテッド 目の障害および状態を治療するための組成物および方法
DE502004009901D1 (de) 2004-07-22 2009-09-24 Aquanova Ag Solubilisate von ätherischen ölen und anderen stoffen
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
EP1796625A4 (en) 2004-08-06 2009-07-15 Transform Pharmaceuticals Inc NEW FENOFIBRATE FORMULATIONS AND RELEVANT TREATMENT METHODS
CA2577345C (en) 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
WO2006022291A1 (ja) 2004-08-27 2006-03-02 Senju Pharmaceutical Co, .Ltd. ドライアイ治療用点眼液
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
BRPI0607569A2 (pt) 2005-03-08 2009-09-15 Reliant Pharmaceuticals Inc composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
US20060223737A1 (en) 2005-03-25 2006-10-05 L'oreal Foaming O/W emulsion and use thereof in cosmetics
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20090053306A1 (en) 2005-09-29 2009-02-26 Agarwal Rajesh K Pharmaceutical Compositions of a 5-HT2A Serotonin Receptor Modulator Useful for the Treatment of Disorders Related Thereto
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
KR101292573B1 (ko) * 2005-11-11 2013-08-12 모치다 세이야쿠 가부시키가이샤 젤리 조성물
AU2006316507B2 (en) 2005-11-22 2012-11-01 Nestec S.A. Oil-in-water emulsion and its use for the delivery of functionality
JP2009520824A (ja) 2005-12-20 2009-05-28 セネストラ エルエルシー オメガ３脂肪酸製剤
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
TW200836771A (en) 2006-10-31 2008-09-16 Kaneka Corp Particulate composition comprising bioactive substance and method of producing the same
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
CA2692394A1 (en) 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
CN101380358B (zh) 2008-10-14 2012-12-19 沈阳药科大学 精制紫苏籽油脂肪乳注射液及制备工艺
WO2010119319A1 (en) 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
AU2009344374B2 (en) 2009-04-17 2015-07-23 Innovaoleo, Slu Compositions rich in omega-3 fatty acids with a low content in phytanic acid
CA2759176C (en) 2009-04-29 2016-03-15 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3181131A1 (en) * 2009-05-22 2017-06-21 Mochida Pharmaceutical Co., Ltd. Self-emulsifying compositin of 3 fatty acid
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20110045050A1 (en) 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
EP2490678B1 (en) * 2009-10-23 2021-08-04 Basf As Coated capsules and tablets of a fatty acid oil mixture
AU2010319539B2 (en) 2009-11-10 2015-10-22 Mycell Technologies, Llc Stabilized formulations of fatty acids
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
WO2012032415A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
WO2012037328A2 (en) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
JP2015514683A (ja) 2012-02-16 2015-05-21 ブライトサイド イノベーションズ，インコーポレイティド 食品性栄養組成物および使用方法
HK1204978A1 (zh) 2012-03-30 2015-12-11 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物

Also Published As

Publication number Publication date
KR102193214B1 (ko) 2020-12-18
DK3072510T3 (da) 2019-08-12
EP3072510B1 (en) 2019-05-08
US9302017B2 (en) 2016-04-05
US20140348929A1 (en) 2014-11-27
US9364562B2 (en) 2016-06-14
MX2014011596A (es) 2015-07-06
HRP20191392T1 (hr) 2019-12-27
US9375490B2 (en) 2016-06-28
US9364559B2 (en) 2016-06-14
HK1204978A1 (zh) 2015-12-11
US9302016B2 (en) 2016-04-05
CO7121328A2 (es) 2014-11-20
ES2741560T3 (es) 2020-02-11
CN104321053A (zh) 2015-01-28
EP2830602B1 (en) 2020-10-21
PT3072510T (pt) 2019-08-22
WO2013148136A1 (en) 2013-10-03
US20150328326A1 (en) 2015-11-19
US20140348930A1 (en) 2014-11-27
US9364561B2 (en) 2016-06-14
MY189576A (en) 2022-02-17
RU2633862C2 (ru) 2017-10-18
IL249821A0 (en) 2017-02-28
IN2014DN08449A (enExample) 2015-05-08
US20150328327A1 (en) 2015-11-19
US20150328324A1 (en) 2015-11-19
US9370585B2 (en) 2016-06-21
US20150328177A1 (en) 2015-11-19
JP6359517B2 (ja) 2018-07-18
US9364558B2 (en) 2016-06-14
AU2013240427A1 (en) 2014-09-25
US9364560B2 (en) 2016-06-14
KR20140145597A (ko) 2014-12-23
EP2830602A1 (en) 2015-02-04
US20150328325A1 (en) 2015-11-19
IL234814A (en) 2017-11-30
US20150328178A1 (en) 2015-11-19
AU2013240427B2 (en) 2017-08-03
EP3072510A1 (en) 2016-09-28
JP2015514083A (ja) 2015-05-18
IL249821B (en) 2019-04-30
RU2014141406A (ru) 2016-05-20
CA2867168A1 (en) 2013-10-03
CN109966279A (zh) 2019-07-05
US20150328153A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
MX359711B (es) Composiciones de éster de ácido graso omega-3.
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
MX2014000770A (es) Composiciones de acidos grasos.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
MX2016016173A (es) Forma de dosis oral solida de compuestos lipofilicos.
NI201100013A (es) Salicilatos acetilados con ácidos grasos y sus usos.
WO2014057362A3 (en) Omega -3 compositions
CL2015002713A1 (es) Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio.
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
MX2015007938A (es) Composicion nutricional oral con baja viscosidad y alta densidad calorica y metodos relacionados.
BR112017022209A2 (pt) composição aquosa que compreende éster de ácido omega- aminocarboxílico e álcool graxo e seu uso
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112015024040A2 (pt) preparação alergênica
CL2015001138A1 (es) Retiro de componentes indeseados de las composiciones de aceite
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
IN2014DN07483A (enExample)
EA201171150A1 (ru) Композиции моноглицеридов жирных кислот
CL2017000867A1 (es) Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías
MX363035B (es) Uso de una composicion que comprende aceite de pescado y jugo para el tratamiento de inflamacion.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
AR087254A1 (es) Gliceratos de metales alcalinos y alcalinoterreos para la desacidificacion y secado de esteres de acidos grasos
MX2015007436A (es) Forma de dosificacion oral solida de derivado de testosterona.

Legal Events

Date Code Title Description
FG Grant or registration